Study Stopped
Accrual rate fell far below needed accrual rate.
The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer
ECOvar
1 other identifier
observational
7
1 country
4
Brief Summary
The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2021
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 13, 2021
CompletedFirst Submitted
Initial submission to the registry
April 22, 2022
CompletedFirst Posted
Study publicly available on registry
April 28, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 13, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 13, 2023
CompletedApril 22, 2024
April 1, 2024
1.9 years
April 22, 2022
April 18, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival three years after end of therapy
Overall survival three years after the end of primary therapy / start of follow-up
3 years
Secondary Outcomes (7)
Time to Recurrence
3 years
Total number of tumor relapses
3 years
Well-being
3 years
Amount and frequency of patient data entries
3 years
Platinum-sensitivity and the patients' platinum free interval (PFI)
3 years
- +2 more secondary outcomes
Interventions
The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
Eligibility Criteria
Women ≥ 18 years old with a primary ovarian cancer diagnosis.
You may qualify if:
- Women aged ≥ 18 years
- Between diagnosis and the first follow-up visit after the end of their antineoplastic treatment (systemic therapy or surgical treatment) for ovarian cancer.
- German, English, French, or Italian speaking
- Personal smartphone (iOS or Android system); one of the latest three main versions
You may not qualify if:
- Patients whose compliance must be questioned, e.g. due to a psychiatric disorder, private life situation or insufficient knowledge on smartphone use and do not have a suitable caregiver to assist them with symptom reporting.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Stiftung Swiss Tumor Institutelead
- Klinik Hirslanden, Zurichcollaborator
- Manja Gideon Foundationcollaborator
Study Sites (4)
Spital Limmattal Frauenklinik
Schlieren, Canton of Zurich, 8952, Switzerland
Gynäkologische Onkologie Spital Zollikerberg
Zollikerberg, Canton of Zurich, 8125, Switzerland
Praxis für Gynäkologie und Geburtshilfe
Zurich, 8002, Switzerland
Interdisziplinäre Medizin Zürich (IMZ)
Zurich, 8008, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pius Wyss, Prof.Dr.med
Swiss Tumor Institue
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 22, 2022
First Posted
April 28, 2022
Study Start
December 13, 2021
Primary Completion
November 13, 2023
Study Completion
November 13, 2023
Last Updated
April 22, 2024
Record last verified: 2024-04